-
-
Overview
-
Specificity: Anti-RANKL In Vivo Antibody - Low Endotoxin (IK22/5) recognizes an epitope on Mouse RANKL
Purification method: This monoclonal antibody was purified using multi-step affinity chromatography methods such as Protein A or G depending on the species and isotype.
Isotype Control: Rat IgG2a In Vivo Isotype Control - Low Endotoxin [1-1] (ICH2244)
Endotoxin: ≤ 0.75 EU/mg as determined by the LAL method
Aggregation: Aggregation level ≤ 1%Please contact us at for specific academic pricing.
Background
RANKL (Receptor Activator for Nuclear Factor κ B Ligand), also known as TNF-related activation-induced cytokine (TRANCE), osteoprotegerin ligand (OPGL), and ODF (osteoclast differentiation factor), is a member of the tumor necrosis factor family cytokine. RANKL is essential for osteoclast formation, activation, and survival. RANKL through interaction with its receptor RANK can modulate matrix degradation and inflammation. RANKL and RANK have essential roles in lymph node formation, establishment of the thymic microenvironment, and development of a lactating mammary gland during pregnancy. Consequently, novel drugs specifically targeting RANK, RANKL, and their signaling pathways in osteoclasts are expected to revolutionize the treatment of various ailments associated with bone loss, such as arthritis, periodontal disease, cancer metastases, and osteoporosis.
-
- Properties
- Applications
- Reference
-
Overview